Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Retagliptin and Glyburide in Healthy Volunteers
NCT02815787Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of retagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration of SP2086 at Day 25, Maximum Plasma Concentration of SP2086 Acid at Day 25 and 4 more. Started Mar 2014; status: completed.
02
Drugs
retagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02815787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02815787.